Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60.

The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year over year and beating the consensus of $21.58 billion.

Operational growth was 4.2%, and adjusted operational growth was 3.3%. Innovative Medicine sales increased 2.3% or 4.2 operationally to $13.90 billion.

Also Read: Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, Spravato (esketamine) Neuroscience, and Xarelto in cardiovascular. Growth was partially offset by an approximate (810) basis points impact from Stelara (ustekinumab) in immunology.

Cancer sales increased to $5.68 billion, up 17.9% (+20.4 operational).

Immunology sales fell to $3.71 billion, down 12.7% (down 10.9% operational).

Stelara sales fell 33.7% to $1.63 billion. Darzalex sales rose 20.3% to $3.24 billion. The company’s cancer cell therapy, Carvykti, generated sales of $369 million.

MedTech sales increased 2.5% to 8.02 billion, driven primarily by Abiomed in cardiovascular and wound closure products in general surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics.

Dividend: Johnson & Johnson also announced an increase in its quarterly dividend from $1.24 to $1.30 per share. The 4.8% increased dividend is payable on June 10, with a record date of May 27.

Guidance: Johnson & Johnson expects 2025 sales of $91 billion-$91.8 billion versus prior guidance of $90.9 billion–$91.7 billion and consensus of $90.62 billion

The Medtech giant expects 2025 adjusted operational EPS of $10.50-$10.70, compared to prior guidance of $10.75–$10.95. It maintained the adjusted EPS outlook of $10.50-$10.70 versus the consensus of $10.50.

Adjusted operational EPS excluded the impact of translational currency, which means JNJ anticipates a hit to the bottomline from the impact currency.

The company anticipates second-half operational sales growth higher than the first half of 2025.

Johnson & Johnson said the increase in full-year 2025 operational sales guidance reflects the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition.

Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, the company maintains a full-year 2025 adjusted reported EPS outlook of 6.2% growth at the mid-point.

In March, Johnson & Johnson announced its plans to invest more than $55 billion in the U.S. over the next four years.

Price Action: JNJ stock is down 0.88% at $153.01 during the premarket session at the last check Tuesday.

Read Next:

• BofA Sees Mostly Inline Q1 For Industrials, Highlights 3M, JCI, GE Vernova As Top Picks

Photo via Shutterstock